Hoth Therapeutics, Inc. announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.89 USD | -4.30% |
|
-2.93% | -38.19% |
16/07 | Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients | CI |
14/05 | Hoth Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.19% | 49.84L | |
+56.91% | 85TCr | |
+31.59% | 63TCr | |
-0.73% | 36TCr | |
+15.00% | 32TCr | |
+12.34% | 30TCr | |
+15.06% | 24TCr | |
+16.70% | 23TCr | |
+15.89% | 18TCr | |
+4.14% | 17TCr |
- Stock Market
- Equities
- HOTH Stock
- News Hoth Therapeutics, Inc.
- Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients